P. Escribano-Subias (Madrid, Spain), O. Sitbon (Le Kremlin-Bicêtre, France)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Controversies over the impact of the COVID-19 pandemic on patients with Pulmonary Arterial Hypertension
N. Bertici (Timisoara (Timis), Romania), L. Dobrescu (Timisoara (Timis), Romania), L. Pislaru (Timisoara (Timis), Romania), I. Marincu (Timisoara (Timis), Romania)
|   |
Impact of Sars-CoV-2-Pandemic on mental disorders and quality of life in patients with pulmonary arteriaI hypertension
D. Park (Hannover, Germany), J. Fuge (Hannover, Germany), T. Meltendorf (Hannover, Germany), K. Kahl (Hannover, Germany), M. Richter (Giessen, Germany), H. Gall (Giessen, Germany), H. Ghofrani (Giessen, Germany), J. Kamp (Hannover, Germany), M. Hoeper (Hannover, Germany), K. Olsson (Hannover, Germany)
| |
Impact of 3-months COVID-19 lockdown on exercise capacity in stable pulmonary arterial hypertension
C. Baratto (Milano, Italy), S. Caravita (Milano, Italy), C. Dewachter (Bruxelles, Belgium), G. Parati (Milano, Italy), J. Vachiéry (Bruxelles, Belgium)
| |
The lived experiences of people shielding with pulmonary hypertension during the first wave of the COVID-19 pandemic
I. Armstrong (Sheffield (South Yorkshire), United Kingdom), C. Billings (Sheffield (South Yorkshire), United Kingdom), S. Clayton (Sheffield (South Yorkshire), United Kingdom), D. Kiely (Sheffield (South Yorkshire), United Kingdom), J. Sephton (Sheffield (South Yorkshire), United Kingdom), J. Smith (Sheffield (South Yorkshire), United Kingdom), M. Ferguson (Sheffield (South Yorkshire), United Kingdom)
| |
Sildenafil for treatment of associated pulmonary hypertension in patients with severe COVID-19 pneumonia.
I. Qamar (London, United Kingdom), J. May (London, United Kingdom), A. Anwar (London, United Kingdom), N. Bascon (London, United Kingdom), A. Crerar-Gilbert (London, United Kingdom), B. Madden (London, United Kingdom)
| |
Predictive value of CT pulmonary angiography to assess surgical accessibility for pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension (CTEPH) patients
T. Frauenfelder (Zurich, Switzerland), M. Mcinnis (Toronto, Canada), M. Eberhard (Zurich, Switzerland), M. De Perrot (Toronto, Canada), S. Ulrich (Zurich, Switzerland), I. Inci (Zurich, Switzerland), I. Opitz (Zurich, Switzerland)
| |
Type of anticoagulant therapy as a risk factor for the severity of chronic thromboembolic pulmonary hypertension
A. Bokan (Loewenstein, Germany), G. Staehler (Loewenstein, Germany), A. Kempa (Loewenstein, Germany), A. Volk (Loewenstein, Germany)
| |
The changing epidemiology of pulmonary hypertension: disease characteristics and clinical outcome over two decades of the swiss registry
P. Appenzeller (Zürich, Switzerland), M. Lichtblau (Zürich, Switzerland), C. Berlier (Zürich, Switzerland), J. Aubert (Lausanne, Switzerland), A. Azzola (Lucerne, Switzerland), J. Fellrath (Neuenburg, Switzerland), T. Geiser (Bern, Switzerland), F. Lador (Geneva, Switzerland), S. Pohle (St. Gallen, Switzerland), I. Opitz (Zurich, Switzerland), M. Schwerzmann (Bern, Switzerland), H. Stricker (Locarno, Switzerland), M. Tamm (Basel, Switzerland), S. Saxer (Zurich, Switzerland), S. Ulrich (Zurich, Switzerland)
| |
Geographical barriers in access to pulmonary arterial hypertension care in Brazilian public health system
T. Rocha (Belo Horizonte (MG), Brazil), C. Pinto (Salvador (BA), Brazil), P. Fiuza (Salvador (BA), Brazil), A. Lemos (Salvador (BA), Brazil)
| |
Patterns of pulmonary hypertension in Egyptian patients with COPD: A retrospective analysis
M. Atta (Alexandria, Egypt), Y. Khalil (Alexandria, Egypt), A. Elbehairy (Alexandria, Egypt), T. Morsi (Alexandria, Egypt)
| |
Spectrum of interstitial lung diseases (ILDs) and associated prevalence of pulmonary hypertension
R. Tyagi (Lucknow (UP), India), S. Kant (Lucknow (UP), India), A. Wakhlu (Lucknow (UP), India), A. Parihar (Lucknow (UP), India), A. Pradhan (Lucknow (UP), India), R. Jaiswal (Lucknow (UP), India)
| |
The effect of lung diseases on pulmonary hypertension and the effect of pulmonary hypertension on the lung
I. Güzelkas (Ankara, Turkey), B. Özsezen (Ankara, Turkey), D. Ademhan Tural (Ankara, Turkey), B. Sunman (Ankara, Turkey), H. Nayir Büyüksahin (Ankara, Turkey), E. Aypar (Ankara, Turkey), T. Karagöz (Ankara, Turkey), N. Emiralioglu (Ankara, Turkey), E. Yalçin (Ankara, Turkey), D. Dogru (Ankara, Turkey), U. Özçelik (Ankara, Turkey), N. Kiper (Ankara, Turkey)
| |
Whipple’s disease: a rare and life-threatening cause of pulmonary hypertension
E. Jutant (Le Kremlin Bicêtre, France), A. Roche (Le Kremlin Bicêtre, France), A. Boucly (Le Kremlin Bicêtre, France), A. Camboulive (Le Kremlin Bicêtre, France), M. Jevnikar (Le Kremlin Bicêtre, France), X. Jais (Le Kremlin Bicêtre, France), O. Sitbon (Le Kremlin Bicêtre, France), M. Humbert (Le Kremlin Bicêtre, France), L. Savale (Le Kremlin Bicêtre, France), D. Montani (Le Kremlin Bicêtre, France)
| |
Charactaristics and prognosis of autoimmune antibody-positive patients of idiopathic pulmonary arterial hypertension
M. Sakayori (Chiba, Japan), A. Sekine (Chiba, Japan), N. Tanabe (Chiba, Japan), A. Naito (Chiba, Japan), T. Jujo (Chiba, Japan), T. Sugiura (Chiba, Japan), A. Shigeta (Chiba, Japan), S. Sakao (Chiba, Japan), K. Tatsumi (Chiba, Japan)
| |
Distance assessment of the risk of pulmonary hypertension associated with connective tissue diseases: do biomarkers help?
A. Volkov (MOSCOW, Russian Federation), O. Alexeeva (MOSCOW, Russian Federation), E. Nikolaeva (MOSCOW, Russian Federation)
| |
Risk assessment in Pulmonary Arterial Hypertension (PAH) based on the Simplified French Model: A single centre experience
U. Falak (Newcastle Upon Tyne, United Kingdom), K. Lekhak (Newcastle Upon Tyne, United Kingdom), M. Athar (Newcastle Upon Tyne, United Kingdom), R. Crackett (Newcastle Upon Tyne, United Kingdom), J. Lordan (Newcastle Upon Tyne, United Kingdom), G. Macgowan (Newcastle Upon Tyne, United Kingdom), A. Fisher (Newcastle Upon Tyne, United Kingdom), A. Nair (Newcastle Upon Tyne, United Kingdom)
| |
Abnormal right ventricular to pulmonary artery coupling in sickle cell disease
T. Ballez (Bruxelles, Belgium), F. Benghiat (Bruxelles, Belgium), C. Dewachter (Bruxelles, Belgium), A. Roussoulières (Bruxelles, Belgium), J. Vachiéry (Bruxelles, Belgium)
| |
Impact of cyanosis on ventilatory kinetics during stairclimbing in pulmonary arterial hypertension
C. Samaranayake (London, United Kingdom), Y. Luo (London, United Kingdom), K. Siewers (London, United Kingdom), C. Warren (London, United Kingdom), S. Craig (London, United Kingdom), C. Harries (London, United Kingdom), L. Price (London, United Kingdom), A. Kempny (London, United Kingdom), M. Gatzoulis (London, United Kingdom), K. Dimopoulos (London, United Kingdom), N. Hopkinson (London, United Kingdom), S. Wort (London, United Kingdom), J. Hull (London, United Kingdom), C. Mccabe (London, United Kingdom)
| |
Effects of a daytrip to high altitude (2500m) in pulmonary hypertension.
S. Schneider (Zürich, Switzerland), L. Mayer (Zürich, Switzerland), M. Lichtblau (Zürich, Switzerland), C. Berlier (Zürich, Switzerland), E. Schwarz (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), L. Tan (Zürich, Switzerland), K. Bloch (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland)
| |
Late Breaking Abstract - COVID-19 in patients with pulmonary hypertension: a national prospective cohort study
D. Montani (Le Kremlin-Bicêtre, France), M. Certain (Le Kremlin-Bicêtre, France), L. Savale (Le Kremlin-Bicêtre, France), X. Jaïs (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), O. Sitbon (Le Kremlin-Bicêtre, France), -. And The French P.H Network Pulmotension Investigators (Pulmotension, France)
| |